Can RNAi be used as a weapon against COVID-19/SARS-CoV-2?

Kawalpreet K Aneja1*, Niketa Dixit2 and Arun Kumar3

1Independent Scholar, Previous Research Fellow UPENN, Biology Educator at Randolph Career and Technical Institute, Philadelphia 19104, USA.
2Research Assistant, Bioprosthetics Inc, Newark DE 19703, USA.
3Chief scientist, Bioprosthetics Inc, Newark DE 19703, USA.

*Correspondence: kaneja@hotmail.com

Abstract
Can RNA interference be used as a diagnostic and therapeutic for COVID-19? Can host or viral encoded miRNA or siRNA be used as a vaccine against SARS-CoV-2? RNAi has been used as a platform to make attenuated viral vaccines where the viral genome is engineered and modified to contain miRNA or siRNA binding sites [50]. One of these examples was the creation of self-attenuating Influenza A virus strain that expressed an siRNA from the NS segment (for wild type nonstructural protein NS1) that targets the ORF of the nucleoprotein [NP] segment just at a single site [51]. Intranasal administration of five chemically modified miRNA mimics corresponding to highly expressed miRNAs in respiratory epithelial cells synergistically suppressed H1N1 replication in mice. MicroRNA 122 is another most common example in RNAi literature, antimiR against mir-122 is effective to lower the hepatitis C virus and miR-122 inhibition by anti-miR122 also reduces serum cholesterol levels [40,52]. RNAi patents and clinical trials for liver cancer, breast cancer, lymphoma, melanoma, IAV, are just a few examples and there are hopes for COVID-19 soon. How about the plant-based diet and plant microRNAs, can we use them against COVID-19 like infections? This mini-review discusses different types of non-coding small RNA molecules, their biogenesis, the role of innate immune response and the competition of proviral and antiviral proteins, and how RNAi can be alone or as a combination of COVID-19 intervention drugs and vaccines used as a therapeutic along with a little emphasis on plant-based miRNAs to prevent future pandemics like COVID-19?

Keywords: RNAi, Non-Coding Small RNAs, miRNA, siRNA, Drosha, Dicer, Argonaute Complex, COVID-19, Pattern Recognition Receptors, Interferon, IFN-regulatory factors, IFN-stimulatory genes, Cytokine storm, Vaccine, Plant miRNA

Introduction
RNAi means active cell response to foreign RNA [1]. RNAi is a major defense mechanism against alien nucleic acids of bacteria, viruses, and phages; RNAi is present in diverse organisms like fungi, plants, algae [2], invertebrates, and vertebrates including mammals. RNAi is known for at least the last two decades, is a double-stranded short interfering RNA (siRNA) or microRNA (miRNA) of approximately 21-23 nucleotides that can target the degradation or prevent the translation of an mRNA which contains complementarity to it [3].

Review
What is RNA Interference?
RNA interference (RNAi) is not interference but is a process where noncoding RNA regulates gene expression, protein expression, RNA splicing, RNA silencing, chromatin structure, modifications, and segregation [3]. RNAi plays a big role in various biological phenomena like cell proliferation, cell death, fat metabolism in flies, neuronal patterning in nematodes, regulation of hematopoietic cells, and differentiation in mammals, root, stem, and leaves formation in plants [4], etc.

What are the different types of Small RNA Molecules?
Based upon the whole genome and transcriptome sequencing projects, and RNAi experiments, there are three main types of small RNAs: microRNA or miRNA, small interfering RNA or siRNA, & piwi-associated RNA or piRNA.
1. miRNA: They are 20-25 nucleotides long. Gene regulatory
What led to the serendipitous discovery of RNAi?

RNAi was first discovered in plants when enhancing the color of petunias via plasmid containing chalcone synthase gene led to co-silencing of its transgene and homologous gene which resulted in totally white or patterned flowers with white or pale non-clonal sectors on a wild-type pigmented background [10]. During the same time, Doughtery’s lab discovered the Tobacco Etch Virus (TEV) coat protein antisense RNA induced resistance against its infection in Nicotiana tabacum plants [11]. Another milestone in RNAi was made by Andrew Fire and Craig C. Mello in Caenorhabditis elegans, double-stranded RNA but not the single-stranded RNA against unc-22, unc-54, fem-1, and hli-h genes successfully silenced the targeted genes which led them to 2006 Nobel Prize in Physiology or Medicine [12-14]. But all of this started from the discoveries of small temporal RNAs by Lee et al., 1993 [15] and Reinhart et al., 2000 [16]. The word RNA made a different meaning after Dr. Lee’s discovery of the lin-4 gene that codes a precursor of 61 nucleotides to make 22 nt miRNA. This 22 nt miRNA represses lin-14 by complementarily binding at 7 sites of its 3’UTR [16,17]. The expression of lin-14 is required to transit C. elegans from the first larval stage to the second larval stage. From lin-4 to let-7 in C. elegans, Drosophila, soon non-coding RNAs were discovered in humans, other bilateral animals, fungi, algae, plants and certain DNA viruses [10].

How are small RNA molecules made?

They are derived from larger RNA precursors, imperfect hairpin loop structure in case of miRNA, and perfect double-stranded RNA in case of siRNA. Both miRNA and siRNA genes at first are transcribed by RNA polymerase II and are known as primary miRNAs or pri-miRNAs or pri-siRNAs [18]. There are three major steps of biogenesis of mature and processed small RNA molecules (Figure 1).

1. The pri-miRNAs are processed into precursor miRNAs (pre-miRNAs) by the Microprocessor complex, consisting of the ribonuclease RNase III Drosha and DiGeorge Syndrome Critical Region 8 (DGCR8).

2. After synthesis of pre-miRNAs takes place in the nucleus they are exported into the cytoplasm by the Exportin 5 protein, where they are processed by a specialized RNase III-like enzyme named Dicer into smaller dsRNA molecules. Each pre-miRNA has two strands; the antisense strand to the targeted mRNA is referred to as the guide strand and its base-paired sense strand known as the passenger strand [19,20].

3. Both pre-miRNA strands are transferred by Dicer and its cofactors TRBP (TAR RNA binding protein) and PACT (Protein kinase RNA activator) into an Argonaute (AGO2 in mammals) containing RISC complex. This complex formation first destroys the passenger strand and then only the guide strand in RISC-complex is targeted at the mRNA, which can degrade the target mRNA or destabilize it to block the translation [19].

Dicer is not always required for the processing of pre-miRNA. There are two ways of miRNA processing– canonical or non-canonical. Canonical miRNAs processing depends upon the dicer and non-canonical miRNA does not require Dicer and Microprocessor complex. For example, the mirtron pathway, which is found in D. melanogaster and C. elegans, produces pre-miRNAs by the processing of introns by spliceosomes and debranching enzymes (not by dicer) in the nucleus, is an example of the non-canonical pathway [19]. The target mRNA recognition is initiated by a short nucleotide stretch at the 5’ end of the miRNA (position 2–8), the so-called seed sequence, accompanied by various degrees of base pairing at the 3’ end [19]. In contrast to miRNA, siRNA target recognition requires base pairing of entire small RNA and subsequent target cleavage by AGO2. Guide pre-miRNA targets the RISC complex to 3’UTR or other parts of mRNA results in translational inhibition, mRNA cleavage, de-adenylation, or histone and DNA methylation [3].

RNA interference as a vaccine

We do not live in 1,000 AD anymore where a charlatan would...
make a cut in the skin and transfers smallpox scabs from a patient into a normal human to immunize against smallpox. Our vast information on immunology and a spectrum of lab tools are at an edge in a way that we should be able to temporarily provide some kind of vaccine against any outbreak at any time.

The first experiment where RNAi was used as therapeutics was to prevent hepatitis. When mouse hepatocytes were injected with Fas siRNA they were resistant to Fas-induced apoptosis and hepatocyte necrosis upon exposing cells to Fas antibody or concanavalin-A (ConA). These experiments demonstrated the therapeutic value of Fas siRNA for preventing liver insults induced by viral, autoimmune hepatitis, and liver disorders [21, 22]. Can we use small ncRNA molecules as a treatment against viral infections? But we first start with what happens in the waging battle between virus and host?

**Telltale of Virus vs Host RNAi**

How do cells distinguish between self and viral DS-, SS-DNA, or RNA and their modified forms?

Viruses contain different types of the genome like long dsDNA, dsRNA, 5’triphosphate, or 5’-diphosphate dsRNA, ssRNA, CpG motifs in ssDNA, and short dsDNA with guanosine-containing overhangs [19, 23, 24]. The host cell can distinguish itself from nonself-genomic material. Cells have evolved a system of identifying own nucleic acid material from the foreign one by modifying it, for example, 2’-Omethylation at the N1 position of capped RNA eliminates recognition by RIGI and IFIT1, but if 2’-Omethyl groups or other modifications such as pseudouridine are added at internal positions of RNA that prevents recognition by TLR7, TLR8, and MDA5 [24]. The C5 methylation of CpG motifs in DNA abolishes TLR9 recognition [24]. Vaccinia virus expresses an enzyme poly-A polymerase known as VP55, which is not only responsible for polyadenylation of viral mRNAs but also cellular miRNAs that results in degradation of mature miRNAs to allow viral sustenance, maybe that is how cellular RNAs and modified miRNAs were evolved for 2’-Omethylation to avoid degradation [40, 41, 42, 45].

The immune response to viral genomes depends upon their structure, concentration or availability, localization inside, or outside the cell [24]. There are different types of cell receptors to recognize different nucleic acid molecules. These are categorized into first-line and second-line nucleic acid receptors. The pattern recognition receptors (PRRs) of the Toll-like receptor (TLR3, TLR7, TLR8, & TLR9); the RIGI-like receptor (RLR) family of RNA sensors (also known as DDXS8);
melanoma differentiation-associated gene 5 (MDA5; also known as IFIH1); the DNA sensors absent in melanoma 2 (AIM2) and cyclic GMP–AMP synthetase (cGAS) come under first-line receptors category [19,23,24] (Figure 2). These first-line receptors instigate a cascade of signaling events that involve MYD88, TRIF, IRAKs, TRAFs, transcription factors like, nuclear factor-kb (NFkB) and IFN-regulatory factor 3 (IRF3), IRF7, and are dominated by type I interferon response and IFN-stimulatory genes (ISGs) [24] (Figure 2).

After Interferon is expressed; it is translocated across the cell membrane; it can signal in an autocrine or a paracrine way via the interferon-a/b receptor consisting of two subunits, IFNAR-1 (IFNAR; IFN receptor) and IFNAR2, this leads to phosphorylation of STAT transcription factors through the JAK-STAT pathway. STAT1 and STAT2 now heterodimerize and translocate to the nucleus to activate a broad range of ISGs (Figure 2). Second-line category receptors comprise nucleic acid receptors with direct antiviral activity, for example, double-stranded RNA (dsRNA)-activated protein kinase R (PKR; also known as eIF2AK2), 2’5’oligoadenylate synthetase 1 (OAS1), adenosine deaminase acting on RNA 1 (ADA1) [24], PKR, OAS1, and ADA1are also known as ISGs. The major difference between first-line and second-line nucleic acid receptors is that the second line receptors do not induce an immune response.

Figure 2: Innate Immune Response and the Role of miRNAs.
Viruses activate innate immune response by pattern recognition receptors (PRRs) like Toll-like receptors, (TLRs) RIG-like receptors (RLRs), NOD-like receptors (NLRs), and C-type lectin receptors (CLRs), only TLRs and RLRs are shown above. Endosomal TLR3s recognize double-stranded RNA, Poly-IC, viral RNA, siRNA, and endogenous mRNA; TLR7 and 8 recognize single-stranded RNA; TLR9 binds to CpG-ODN [44]. TLRs activate the signal pathway that starts from adaptor proteins like TRIF/MyD88 then through IRAK-TRAF6 to transcription factors like IRF3/IRF7/NF-κB/AP-1 which translocate to nucleus and cause type I IFN and subsequent ISGs expression. Secreted type I IFNs can translocate across the cell membrane in an autocrine or a paracrine fashion through IFN-α/β receptor, this activates the phosphorylation of STAT1 and STAT2 via JAK family kinases, JAK-1 and TYK2. Phosphorylated STATs heterodimerize and translocate to the nucleus to activate a broad range expression of ISGs [19,24]. Besides TLRs, RIG-1 and MDA5 detect dsRNA in the cytosol and activate MAVS to induce type I IFN production via IRF3-IRF7; MDA5 also activates apoptosis and signals NLRP3 inflammasome formation which causes pyroptosis [19,24]. The second line receptors PKR, OAS1, IFIT1 directly destroy viral RNA by cleavage, modification, or translational inhibition. Red arrows represent inhibition by miRNAs. Human Influenza type A (NS1) inhibits phosphorylation of IRF3. Viral proteins B2, NS1, VP35, N1, and viral miRNAs miR-485, miR-342 inhibit the IFN-response pathway. MiR-144 is a proviral and miR-146a is an antiviral for HCV. miR-146a of EV71 suppresses IRAK1 and TRAF6 [23]. MiR-144 is a positive regulator of RNA viruses by targeting TRAF-6, miR-485 reduces the expression of Interferon and IL-6, miR-485 targets RIG-1 3’ UTR, miR-155, miR-223, and miR-136 are induced by RIG-1/NK/NFkB pathway and inhibit replication of VSV [23], let-7 inhibits IL-6 translation. MiR-466i acts on IFN-α and let-7b on IFN-β. Adenovirus VA1 RNA inhibits PKR or OAS1 degradation [40]. Fig2 is inspired from ref 19, 24, 40, 59 & 61, 82.
response by transcription factors or cytokines but directly destroy viral RNA by cleavage, modification, or translational inhibition \[24\]. Different TLRs responses lead to different outcomes, for example, TLR7 and TLR9 on plasmacytoid dendritic cells lead to type I IFN production while TLR8 on myeloid cells release IL-12 \[24\] (**Figure 2**). Overall excitement of innate immune response causes a storm of cytokines, chemokines, antiviral proteins that directly or indirectly, with or without adaptive immune response, cause the end of the viral realm by preventing viral replication, transcription, translation, virus assembly which ultimately leads to cell death including apoptosis, necroptosis, and pyroptosis.

**Raging battle of proviral versus antiviral factors**

From first-line to second-line nucleic acid receptors as mentioned above, then to IRF3/IRF7, STAT1 or STAT2, NF-κB, signaling transcription factors cascade to finally type I and type III interferon response, and expression of interferon stimulatory genes, anywhere in these steps host and virus deploy an arm of miRNAs on this raging war. The host makes miRNAs to destroy viruses and viruses make own miRNAs, and virulence factors (VSRs) to degrade host miRNAs and deploy host proteins for its multiplication \[23\]. On the other hand, host miRNAs destroy viral proviral factors which are important for viral replication. The virus is extremely clever, it can also use its genomic RNA as a sponge or sequester of endogenous host miRNA molecules, to help in its replication, these RNA sequences that share binding sites with host miRNA are known as competitive viral and host RNAs (cvhRNA) \[25\]. Host miRNA can also act as proviral factors and inhibit antiviral host factors, for example, miR-122, that would facilitate viral replication. Here are a few more examples and also see **Table 1**.

---

**Table 1. Examples of Host and Viral miRNAs involved in viral infections.**

| Type of Virus | MiRNA (Host-made) | Viral Replication |
|--------------|------------------|-------------------|
| Hepatitis C (HCV) | miR-196, miR-296, miR-351, miR-431, miR-448 | Inhibits |
| Vesicular stomatitis (VSV) | miR-155 & miR-223 | Inhibits |
| Epstein-Barr (EBV) | miR-155 | Inhibits |
| Dengue virus 2 (DENV2) | miR-150 | Inhibits |
| Enterovirus 71 (EV71) | miR-296-5p, miR-23b | Inhibits |
| Coxsackievirus B3 (CVB3) | miR-342-5p | Inhibits |
| Herpes simplex type 1 (HSV-1) | miR-138 | Inhibits |
| DENV | miR-548g-3p | Inhibits |
| Hepatitis C (HCV) | miR-122 | Helps |
| Bovine viral diarrhea virus (BVDV) | miR-17, Let-7 | Helps |
| Eastern equine encephalitis virus (EEEV) | miR-142-3p | Helps/Inhibits |

2. **Host miRNAs can degrade host proviral factors that help viral replication**

| Virus | MiRNA | Host Protein |
|-------|-------|--------------|
| DENV2 | miR-223 | downregulates the microtubule destabilizing protein stathmin 1 (STMN1) |
| Herpesviruses and alphaviruses | miR-199a-3p | downregulation of ERK/MAPK, oxidative stress and PI3K/AKT pathway |
| WNV | miR-532-5p | downregulates SESTD1 (SEC14 and spectrin domains 1) and TAB3 (TGF-beta activated kinase 1/MAP3K7 binding protein 3) mRNAs |

3. **Viral miRNAs**

| Virus | Non-coding RNA | Function |
|-------|---------------|----------|
| γ-herpesvirus saimiri (HVS) | miR-HSURs | Degrades miR-27 |
| Human cytomegalovirus (HCMV)) | miRNA decay element (miRDE) | degrades miR-17 |
| Epstein-Barr virus (EBV) | (BARTs) | Cancer development |
| Herpes simplex virus 1 | miR-H2-3p | Viral latency |
| West nile virus Kunjin (WNVkun) | Kun-miR-1 | Viral replication enhancement |
| HIV-1 | HIV1-miR-H1 | Cellular apoptosis induction |
| | | Viral protein R (Vpr) stabilization |

From Bruscella et al., 2017 and Girardi et al., 2018.
Can RNAi be used as a diagnostic and therapeutic? What do we need in our quiver to be prepared for an outbreak in the future?

The above examples are evidence of fierce competition between virus and host. Can we learn and use some of these tricks against viral infections? Can we use host or viral miRNA or siRNA or antisense RNAs as an attenuated vaccine? Can we use RNAi therapeutics as intervention drugs against viral infections? Can RNAi be used as a gene therapy against viral infections?

The global antisense & RNAi therapeutics market size is expected to reach USD 1.81 billion by 2025 [47], right now it is about 1.2 billion [47]. RNAi with miRNAs and siRNAs have been successfully used in both diagnostics as signature biomarkers for a particular disease, foreign infection, and the progression of the disease and as a prognostic marker [47-53]. The clinical studies database clinicaltrials.gov includes phase 4 trials with selective miRNAs as biomarkers. These trials have assessed or are actively recruiting patients to examine the profiles of these ncRNA transcripts in a range of health conditions such as diabetes, coronary heart disease, breast cancer, lupus, epilepsy, depressive disorder, stroke, Addison’s disease, influenza, liver disease, and even toxic exposure to agents such as acetaminophen [48]. There is a great need and competition in RNAi as clinical intervention drugs. In 2018, the FDA approved the siRNA drug, Patisiran, for a rare polyneuropathy caused by hereditary transthyretin-mediated (hATTR) amyloidosis. It works by binding and degrading the messenger RNA transcript for transthyretin [54,55]. Many miRNA drugs like MRG110 against miR-92 antiangiogenic miRNA that prevent wound repair in diabetics [56]; MRG-201 for miR-29 to treat keloid and scar tissue formations; MRG-106 for miR-155 in T-cell lymphoma patients are under phase 1 or phase 2 trials [48]. Regulus has announced new miRNA drug RGLS5579 in 2019, this miRNA targets miR-10b for glioblastoma multiforme treatment [48]. First siRNA treatment in human started with ALN-RSV01, a 19 bp RNA duplex with two [2’-deoxy] thymidine overhangs on both 3’ ends to prevent its nuclease degradation, a single site siRNA targeted to the nucleocapsid gene of RSV. The ALN-RSV01 relieves bronchiolitis obliterans when administered by intranasal spray. This drug is made by Alnylam Pharmaceuticals and has reduced a 38% decrease in the number of infected people [62,63]. At least eight anti-HBV siRNAs are in clinical trials [62]. The first synthetic miR-34 was developed in 2013 for the treatment of hepatocellular carcinoma [63]. There has been a success in generating synthetic miRNAs, packing in liposomes, and transfected into the mononuclear cells of peripheral blood. These protocols enhance TNF-α that favors the innate immune response. The PR8-amirR-93NP virus was generated by inserting an expression cassette for miR-93 between viral genes encoding non-structural proteins in an attenuated Influenza virus (IV), and this miRNA specifically targets the nucleoproteins of the IV. This vaccine, administered intranasally, conferred
immunity against several heterologous viral strains [63, 70]. New attenuated vaccines are in trials containing attenuated viruses that are loaded with an expression cassette encoding a synthetic designed miRNA that targets the structural protein of the virus.

How about RNAi against COVID-19, Status Quo

Coronaviruses are enveloped, non-segmented viruses that contain positive-sense single-stranded RNA; the viral genome is in the size from 26 to 32 kilobases, the largest known viral RNA genome [57]. Most of the cells containing cell membrane-bound angiotensin-converting enzyme 2 (ACE2) and associated proteases, transmembrane protease serine 2 (TMPRSS2), and Cathepsin L (CTSL), are identified as the mediators of SARS-CoV2 cellular entry [58, 59]. Single-cell RNA sequencing datasets (sc-RNA-seq) from healthy donors by the Human Cell Atlas revealed that genes that perform an immune response that account for life-threatening respiratory symptoms [60]. The human 47D11 derived monoclonal antibody raised against the receptor-binding domain in spike (S) protein can stop the viral entry. A pair of antibodies isolated from the patient’s convalescent plasma-B38 and H4 block the binding between virus S-protein and ACE2 [61]. The different convalescent blood products to achieve artificial acquired passive immunity have been categorized into 4 types (i) convalescent whole blood (CWB), convalescent plasma (CP) or convalescent serum (CS); (ii) pooled human immunoglobulin (Ig) for intravenous immunoglobulin is the first monoclonal against spike RBD domain in spike (S) protein can stop the viral entry. A pair of antibodies isolated from the patient’s convalescent plasma-B38 and H4 block the binding between virus S-protein and ACE2 [61]. The human 47D11 derived monoclonal antibody raised against the receptor-binding domain in spike (S) protein can stop the viral entry. A pair of antibodies isolated from the patient’s convalescent plasma-B38 and H4 block the binding between virus S-protein and ACE2 [61]. The different convalescent blood products to achieve artificial acquired passive immunity have been categorized into 4 types (i) convalescent whole blood (CWB), convalescent plasma (CP) or convalescent serum (CS); (ii) pooled human immunoglobulin (Ig) for intravenous immunoglobulin is the first monoclonal against spike RBD domain in spike (S) protein can stop the viral entry. A pair of antibodies isolated from the patient’s convalescent plasma-B38 and H4 block the binding between virus S-protein and ACE2 [61].

Inflammatory cytokine storm is the hallmark of COVID-19 which leads to plasma leakage, vascular permeability, and disseminated vascular coagulation and uncontrolled inflammatory response that account for life-threatening respiratory symptoms [60]. The plasma concentrations of IL-1β, IL-1α, IL-7, IL-8, IL-9, IL-10, basic FGF, G-CSF, GM-CSF, IFN-γ, IP-10, MCP-1, MIP-1α, MIP-1β, PDGF, TNFα, and VEGF were higher in both ICU (intensive care unit) patients and non-ICU patients than in healthy adults. Moreover, when comparing ICU and non-ICU patients, plasma concentrations of IL-2, IL-7, IL-10, G-CSF, IP-10, MCP-1, MIP-1α, and TNFα were higher in ICU patients than non-ICU patients, evidence that the cytokine storm is correlated with disease severity [61] (Figure 2). Selected drugs like tocilizumab-sarilumab, baricitinib-fedratinib, and fingolimod are in consideration to manage this storm [60].

Academic laboratories, biotech companies, and the pharmaceutical industries are all involved in the clinical research efforts against COVID-19. There is no cure for COVID-19 except for a few therapeutic drugs that are available for other viruses, e.g., chloroquine and hydroxychloroquine, anti-viral remdesivir, Kaletra which is a combination of lopinavir and ritonavir that works against HIV, favipiravir, and arbidol [65]. In one of the tissue culture experiments for testing efficacy of remdesivir, after 23 passages in Calu-3 2B4 cells, SARS CoV viral RNA-dependent RNA polymerase enzyme mutations at F480L and V557L showed resistance to remdesivir even though these mutations did not affect the pathogenicity of remdesivir in mice [66]. TMPRRS2 cleaves and activates SARS-CoV-2 spike protein and helps in the viral entrance. Camostat mesylate and K11777, a cysteine protease inhibitor inhibits the enzymatic activity of TMPRSS2 [65] (Figure 2).

Monoclonal antibodies represent a major class of passive-immunotherapy treatment against viral infections. Convalescent plasma has been successfully used in various infections like SARS, MERs, influenza, and was started in the Spanish flu pandemic [67]. The different convalescent blood products to achieve artificial acquired passive immunity have been categorized into 4 types (i) convalescent whole blood (CWB), convalescent plasma (CP) or convalescent serum (CS); (ii) pooled human immunoglobulin (Ig) for intravenous or intramuscular administration; (iii) high-titer human Ig; and (iv) polyclonal or monoclonal antibodies [67]. Antibodies from a patient recovering from a viral infection can be transferred or can be manufactured in the lab. The specific monoclonal antibody raised against the receptor-binding domain in spike (S) protein can stop the viral entry. A pair of antibodies isolated from the patient’s convalescent plasma-B38 and H4 block the binding between virus S-protein and ACE2 [61]. The human 47D11 derived from SARS and SARS-CoV-2 and reformatted to a fully human immunoglobulin is the first monoclonal against spike RBD that cross-neutralizes SARS and SARS-CoV-2 in a mechanism independent of receptor-binding inhibition [69]. Companies that are in process of COVID-19 vaccine are Moderna, Inovio, the University of Oxford in England, the University of Queensland in Australia, J&J, Sanofi, etc.

Are there any RNAi therapies for COVID-19?

There are three major steps of COVID-19 infection—viral entry, viral replication, viral maturation, and release. We can design small non-coding RNA molecules to halt this virus at any of these steps. We already have drugs, vaccines, antibodies, as patent or in clinical trials for all of these steps. How about RNAi? Cells affected by human coronavirus activate signal cascades that increase NF-κB1 mRNA and miR-9 expression, miR-9 reduces the translation of NF-κB and can be competed away by OC43 and which allows NFkB translation [63], so miR-9 isa candidate or RNAi since it is induced by the coronavirus to inhibit NFkB pathway. SARS-HcoV mainly infects bronchial-veolar stem cells (BASCs) where they induce overexpression of miR-574-5p and miR-214. Some proteins of the SARS-HcoV viral nucleocapsid downregulate miR-224 and miR-98 expression.
in BASCs and that control several stages of their differentiation as well as pro-inflammatory cytokine production [63, 64]. So we know miR-9, miR-574-5p, miR-214, miR-224, and miR-98 are important targets of coronaviruses and can be used as RNAi therapeutics.

A total of 188 patents are directly associated with anti-SARS and anti-MERS vaccines with a demonstrated immune response [71] (Table 2). Based upon clinicaltrials.gov of 127 potential COVID-19 vaccines are in phase III trial. SARS-CoV-2 mRNA-1273 vaccine which is in phase trial III has shown a safe and strong response in older adults. This vaccine is co-developed by NIAID and Moderna (87). This vaccine contains mRNA-1273 that codes for two prolines substituted at the top of the central helix full length SARS-CoV-2 spike glycoprotein trimer, S-2P. The mRNA is encapsulated in lipid nanoparticles. Other few examples of COVID-19 vaccines are given in Table 2.

There are anti-siRNA patents against four major structural proteins, spike (S), membrane (M) protein, nucleocapsid (N) protein, and envelope (E) proteins of SARS virus, some of them are more than 70% effective. One of the patent applications, CN1569233 discloses siRNAs that target SARS genes encoding RNA-dependent RNA polymerase, helicase, N protein, and proteolytic enzymes (Table 2). Some of the siRNAs were able to inhibit or kill 50−90% of the SARS virus BJ01 strain, with the proteolytic enzyme-targeting siRNAs being the most effective [71]. RNA aptamers, ribozymes, and antisense oligonucleotides have been developed to fight against SARS by reducing its severity, preventing its multiplication steps, detecting, or diagnosing it accurately.

Since human adeno-associated virus (AAV) is a frequent cause of upper respiratory infections, AAV is designed to deliver genes, miRNAs, and siRNAs in the lungs. AAV is about 4.7 kb and has a positive or negative-sensed single-stranded DNA. Because of AAV’s low immune response, it can target both dividing and quiescent cells, makes AAV an attractive vector for gene delivery. Recombinant AAV (rAAV) is constructed by replacing the viral structural (cap) and packaging (rep) genes with the desired transgene along with promoter and polyadenylation sequences [72, 73] (Figure 1).

SARS-CoV-2’s 3’ region of about 10,000 kb encodes for the S, E, M, and N functional proteins, specific miRNAs or siRNAs can be designed to target the sequences for degradation by RISC complex [73]. It can be designed as a vaccine or an intervention drug. There is another great scientific adventure on the horizon, synthesis of asymmetrical siRNAs to target the 5’ and 3’ UTRs and 10 viral ORFs of the ~29 kb SARS-CoV-2 RNA against viral infection [74, 75].

**But there is another twist to this story**

Our diet has many functions including, sustenance, immunomodulatory [81], neuro-modulatory, cardiovascular regulation, auto-immune disorders, and viral infections [79]. What we eat controls our health, personality, and our chance of survival; our genes, miRNAs, transposon elements, proteins, etc., work in synchrony to determine our surrender or victory over known human medical conditions and infections. Since the discovery of rice miR-168a by Zhang et al., 2012, plant-microRNAs have been a hot topic of discussion. The rice miR-168a targets mammalian LDLRAP1 which increases LDL levels in plasma [76]. This has set out scientists all over the world to investigate diet plant miRNAs for the cure and prevention of human medical conditions. How do plant-based diet and plant microRNAs contribute to human well-being?

Plants produce miRNAs that regulate virus replication. MiR-2911 from *Lonicerajaponica*and *Lonicerapericlymenum* target and inhibit Influenza A virus (H1N1, H5N1, H7N9) replication in mice [77, 78]. The miR159 present in plants including, *Arabidopsis thaliana*, *Glycine max*, and *Brassica oleracea*, has a role in breast cancer suppression by targeting the TCF-7 gene [79]. MiR-156a from green vegetables acts as a vasoprotective molecule by targeting the junction adhesive molecule-A (JAM-A), it reduces cytokine-induced monocytes adhesion in endothelial cells [79]. American sweet gum green fruits are used for making an antiflu tincture. The key ingredient in Tamiflu® is oseltamivir phosphate, of which shikimic acid is a precursor, and it is present in green seeds of American sweet gum [80]. We need to do more experiments on deciduous trees of the eastern seaboard to investigate their medicinal importance.

**Future Prospective**

We are still far from fully understanding the molecular mechanisms of networking pathways run by non-coding RNAs in different cells, cell types, plants, and animals, and how they benefit or destroy foreign invaders. There are already many anti-miRNA or antisenseRNA patents and clinical trials against a range of health conditions such as diabetes, coronary heart disease, breast cancer, lupus, epilepsy, depressive disorder, stroke, Addison’s disease, influenza, liver disease, and even toxic exposure to agents such as acetaminophen [48]. We already have patents and clinical trials against Influenza, HBV, HCV, RSV, HIV, and SARS-CoV and SARS-CoV-2. For example, ALN-RSV01, against RSV, administered by intranasal spray, is made by Alnylam pharmaceuticals, has reduced 38% infected patients [62, 63]. Alnylam also has 350 siRNAs in a trial against SARS-CoV-2; Sirnaomica has siRNA formulation via nebulizer (Table 2 [85]). The PRB-amir-93NP virus particle is designed against the Influenza virus and its heterologous strains [73, 70]. RG101 is N-acetylgalactosamine conjugated antisense oligonucleotide which improves its delivery in hepatocytes for sequestration of miR-122 to reduce the HBV burden and relief from its symptoms in patients [40]. These examples are evidence of tremendous hard work by the scientific workforce in the direction of improving healthcare using RNAi and we hope for the SARS-CoV-2 also.

Small non-coding RNAs like miRNA, siRNA, and anti-sense RNAs are very interesting molecules because they induce low immunogenicity, and show cross-species conservation and can be tested in different animal models. But there are...
challenges with design, delivery of live attenuated vaccines, miRNA drugs, and off-target effects. Their safety and toxicity remain a controversial issue.

We are writing so much about different miRNA as a pro- or anti-viral, but all of these mechanisms will vary from lab to lab, the results could be contradictory, but perhaps we can find solutions.

| Group                        | Mechanism of Action                                                                                           | Examples                          |
|------------------------------|---------------------------------------------------------------------------------------------------------------|-----------------------------------|
| Viral entry inhibitors       | Increase in endosomal pH that inhibits viral-cell fusion, proper genome release and efficient infection; Interferes with glycosylation of ACE2 | Hydroxychloroquine, Chloroquine   |
| Viral entry inhibitors       | an inhibitor that may disrupt the binding of viral envelope protein to host cells and prevent viral entry to the target cell, inhibits intracellular vesicular trafficking | Arbidol                           |
| Inhibitors of viral RNA polymerase /RNA synthesis | Prodrug of Adenosine nucleotide analogue, inhibits viral RdRp                                           Remdesivir |
|                               | Guanosine nucleotide analogue, prodrug, inhibits viral RdRp                                                   Faviapiravir                       |
| Inhibitors of viral protein synthesis | Protease inhibitor that may inhibit 3CLpro or PLpro                                                       Lopinavir/ritonavir aka Kaletra    |
| Viral Protease               | Protease inhibitors that may inhibit the viral proteases: 3CLpro or PLpro                                     |                                   |
| JAK signaling inhibitors     | targeting IL-6, inhibiting IL6/JAK/STAT signaling, attenuate the host inflammatory response associated with massive pro-inflammatory cytokine and chemokine storm | Baricitinib-Fedratinib, Fingolimod |

**RNA Therapies**

| RNA Therapies   | Anti-miRNA, anti-siRNA, ribozymes, RNA aptamer, anti-sense oligos, recombinant AAV | Various regions of SARS & MERS          |
|----------------|-----------------------------------------------------------------------------------|----------------------------------------|
| Patents        | US20040192626, siRNA, microRNA, shRNA WO2004092383 WO2018227440 MicroRNA inhibitor microRNAA200c-3p CN101173275 US20050004063 CN1569233 | Applications of mir-200c-3p microRNA in treating lung injuries siRNAs targeting coronavirus proteins M, N, or E of SARS siRNAs targeting replicase and RdRp region of SARS siRNAs targeting RdRp, helicase, nucleoprotein N, and proteolytic enzymes of SARS |

**Companies**

| Alnylam Pharmaceuticals | 350 siRNAs in trial | Against SARS-CoV-2 |
|-------------------------|---------------------|--------------------|
| Sirnaomica              | siRNA formulation by a nebulizer | Against SARS-CoV-2 |
| Other treatments        |                     |                    |
| mRNA-1273 Vaccine       | prolines substitutedSARS-CoV-2 spike glycoprotein trimer, S-2P (87) | Against SARS-CoV-2 |
| BNT162B2 by Pfizer and Biontech | A nucleoside-modified mRNA expresses spike glycoprotein (88) | Against SARS-CoV-2 |
| NVXCoV2373              | spike (S) protein&saponin-based adjuvant (89) | Against SARS-CoV-2 |
| JNJ-78436725 or Ad.26.COV2.S | adenovirus serotype 26 (Ad26) expressing the spike (S) (90) | Against SARS-CoV-2 |
| MRT5500 by Sanofi        | Spike glycoprotein S (91) | Against SARS-CoV-2 |
| Convalescent Plasma      | Convalescent blood products, pooled human immunoglobulins (IgG), mono or polyclonal antibodies | B38 and H4 (68) |

RdRp, RNA-dependent RNA polymerase; coronavirus main protease, (3CLpro), and papain-like protease (PLpro), Table2 adapted from refs 60, 65,68, 69, 71, 83, 84, 85, 87, 88, 89, 90, & 91.
some commonalities in data that can lead us to therapeutical interventions and vaccines against COVID-19 and other viral infections. There is a big scope of plant miRNA therapeutics as a dietary supplement and future medicine.

List of abbreviations
RNAi: RNA interference
HVS: Herpesvirus saimiri
HCMV: Human cytomegalovirus
MCMV: Murine cytomegalovirus
TBSV: Tomato bushy stunt virus
EBV: Epstein-barr virus
CMV: Cucumber mosaic virus
CVB3: Coxsackievirus B3
FHV: Flock House virus
VSV-G: Vesicular somatitis virus G protein
IV: Influenza virus
OAS1: 2’-5’-oligoadenylate synthetase 1
NLRP3: NOD-, LRR- and pyrin domain-containing 3
PKR: Protein kinase R
TIR: Toll-like receptor
RIG-I: Retinoic acid inducible gene I
IRF: Interferon regulatory factor
MYD88: Myeloid differentiation primary response gene
PKR: Protein kinase R
TRIF: TIR domain-containing adapter protein inducing IFN-β
RIG-I: Retinoic acid inducible gene I
PKR: Protein kinase R
NLRP3: NOD-, LRR- and pyrin domain-containing 3

Competing interests
The authors declare that they have no competing interests.

Acknowledgements
I am extremely thankful to Dr. AK for giving me inspiration to write this article. Thanks to Ms. Kinu Aneja for editing this article.

Authors’ contributions

| Authors’ contributions         | KKA | ND | AK |
|-------------------------------|-----|----|----|
| Research concept and design   | ✓   |    |    |
| Collection and/or assembly of data | ✓   |    |    |
| Data analysis and interpretation | ✓  | ✓  | ✓  |
| Writing the article           | ✓   |    |    |
| Critical revision of the article | ✓  |    |    |
| Final approval of article     | ✓   |    |    |
| Statistical analysis          | ✓   |    |    |

Publication history
Editors: Antonio Pedro Fonseca, University of Porto, Portugal.
Received: 26-Sept-2020 Revised: 20-Nov-2020
Accepted: 24-Nov-2020 Published: 17-Dec-2020

References
1. Mello, C., Conte, D. Revealing the world of RNA interference. *Nature* 431, 338–342 (2004).
2. Lyu, J. RNA silencing: Machinery in algae. *Nature Plants* 2, 16070 (2016).
3. Cartef, R. W., & Sontheimer, E. J. (2009) Origins and Mechanisms of miRNAs and siRNAs. *Cell*, 136(4), 642–655. https://doi.org/10.1016/j.cell.2009.01.035
4. Bartel, D. (2004) MicroRNAs: Genomics, Biogenesis, Mechanism, and Function. *Cell*, Vol. 116, 281–297
5. Groths, H., Filipowicz, W. The expanding world of small RNAs. *Nature* 451, 414–416 (2008). https://doi.org/10.1038/451414a
6. Piatek, M. J., & Werner, A. (2014). Endogenous siRNAs: regulators of internal affairs. *Biocbemical Society transactions*, 42(4), 1174–1179. https://doi.org/10.1042/BST20140068
7. Katiyar-Agarwal, S., Gao, S., Vivian-Smith, A., & Jin, H. (2007). A novel class of bacteria-induced small RNAs in Arabidopsis. *Genes & development*, 21(23), 3123–3134. https://doi.org/10.1101/gad.1595107
8. Ghildiyal, M., & Zamore, P. D. (2009). Small silencing RNAs: an expanding universe. *Nature reviews. Genetics*, 10(2), 94–108. https://doi.org/10.1038/ng2504
9. Sioi MC, Sato K, Peciz D, Aravin AA. PIWI-interacting small RNAs: the vanguard of genome defence. Nat Rev Mol Cell Biol. 2011; 12:246–258
10. Napoli C, Lemieux C, Jorgensen R (1990) Introduction of a chimeric chalcone synthase gene into Petunia results in reversible cosuppression of homologous genes in trans. Plant Cell 2:279–289
11. Lindbo J.A, Dougherty W. G. (1992) Untranslatable transcripts of the tobacco etch virus coat protein gene sequence can interfere with tobacco etch virus replication in transgenic plants and proteoplas. *Virology*. 1992;189(2):725-733. doi:10.1016/0042-6822(92)90595-g
12. Fire, A. Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC (1998). “Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans”. *Nature*. 391 (6669): 806–811
13. Daneholt B. “Advanced Information: RNA interference”. The Nobel Prize in Physiology or Medicine 2006.
14. Ambros, V. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell 113, 673–676 (2003).
15. Lee, R.C., Feinbaum, R.L., and Ambros, V. (1993). Cell 75, 843–854.
16. Reinhart, B.J., Slack, F.J., Basson, M., Pasquelli, A.E., Pettinger, J.C., Rougvie, A.E., Horvitz, H.R., and Ruvkun, G. (2000). The 21-nucleotide let-7RNA regulates developmental timing in Caenorhabditis elegans. *Nature*. 403, (6772): 806–811.
17. He, L., Hannon, G. MicroRNAs: small RNAs with a big role in gene regulation. *Nat Rev Genet* 5, 522–531 (2004). https://doi.org/10.1038/nrg1379
18. Castel, Stephane E., and Robert A. Martienssen. “RNA interference in the nucleus: roles for small RNAs in transcription, epigenetics and beyond.” *Nature Reviews Genetics*, vol. 14, no. 2, 2013, p. 100
19. Schuster, S., Miesen, P., & van Rij, R. P. (2019). Antiviral RNA in Insects and Mammals: Parallels and Differences. Viruses, 11(5), 448. https://doi.org/10.3390/v11050048

20. Pei, Y., Tuschl, T. On the art of identifying effective and specific siRNAs. Nat Methods 3, 670–676 (2006). https://doi.org/10.1038/nmeth911

21. Song E, Lee SK, Wang J, et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med. 2003;9(3):347-351.

22. Tan FL, Yin JQ. RNAi, a new therapeutic strategy against viral infection. Cell Res. 2004;14(6):460-466.

23. Bruscella, P., Bottini, S., Baudesson, C., Pawlotsky, J. M., Feray, C., & Trabucchi, M. (2017). Viruses and miRNAs: More Friends than Foes. Frontiers in microbiology, 8, 824.

24. Schlie, Martin, and Gunther Hartmann. “Discriminating self from non-self in nucleic acid sensing.” Nature Reviews Immunology, vol. 16, no. 9, 2016, p. 566

25. Li, C., Hu, J., Hao, J., Zhao, B., Wu, B., Sun, L., et al. (2014). Competitive virus and host RNAs: the interplay of a hidden virus and host interaction. Protein Cell 5, 348–356

26. Talon, J.; Horvath, C.M.; Polley, R.; Basler, C.F.; Muster, T.; Palese, P.; Garcia-Sastre, A. Activation of interferon regulatory factor 3 is inhibited by the influenza virus NS1 protein. J. Virol. 2000, 74, 7989–7996

27. Luna, J. M., Scheel, T. K., Danino, T., Shaw, K. S., Mele, A., Fak, J. J., et al. (2015). Hepatitis C virus RNA functionally sequesters mir-122. Cell 160, 1099–1110. doi:10.1016/j.cell.2015.02.025

28. Chao, J.A.; Lee, J.H.; Chapados, B.R.; Debler, E.W.; Schneemann, A.; Williamson, J.R. Dual modes of RNA-silencing suppression by flock house virus protein B2. Nat. Struct. Mol. Biol. 2005, 12, 952–957.

29. Lingel, A.; Simon, B.; Izaurralde, E.; Sattler, M. The structure of the flock house virus protein B2, a virus suppressor of RNA interference. Nature 2004;14(6):460-466.

30. Shimakami, T., Yamane, D., Jangra, R. K., Kempf, B. J., Spaniel, C., Barton, D. J., et al. (2012). Stabilization of hepatitis C virus RNA by an Ago2-miR-122 complex. Proc. Natl. Acad. Sci. U.S.A. 109, 941–946. doi: 10.1073/pnas.1112263109

31. Sedano, C. D., and Sarnow, P. (2014). Hepatitis C virus subverts liver-specific mir-122 to protect the viral genome from exoribonuclease Xrn2. Cell Host Microbe 16, 257–264. doi:10.1016/j.chom.2014.07.006

32. Masaki, T., Arend, K. C., Li, Y., Yamane, D., McGivern, D. R., Kato, T., et al. (2015). mir-122 stimulates hepatitis C virus RNA synthesis by altering the balance of viral RNAs engaged in replication versus translation. Cell Host Microbe 17, 217–228.

33. Schult, P., Roth, H., Adams, R.L. et al. microRNA-122 amplifies hepatitis C virus translation by shaping the structure of the internal ribosomal entry site. Nat Commun 9, 2613 (2018).

34. Li, Q., Lowey, B., Sodroski, C., Krishnamurthy, S., Alao, H., Chao, J.A.; Lee, J.H.; Chapados, B.R.; Debler, E.W.; Schneemann, A.; Williamson, J.R. Dual modes of RNA-silencing suppression by flock house virus protein B2. Nat. Struct. Mol. Biol. 2005, 12, 952–957.

35. Schult, P., Roth, H., Adams, R.L. et al. microRNA-122 amplifies hepatitis C virus translation by shaping the structure of the internal ribosomal entry site. Nat Commun 9, 2613 (2018).

36. Brochado-Kith, Ó., Gómez Sanz, A., Real, L. M., Crespo García, J., Ryan Murúa, P., Macías, J., Cabezas González, J., Troya, J., Pineda, J. A., Arias Loste, M. T., Diez Viñas, V., Jiménez-Sousa, M. Á., Medrano de Dios, L. M., Cuesta De la Plaza, I., Monzón Fernández, S., Resino García, S., & Fernández-Rodríguez, A. (2019). MicroRNA Profile of HCV Spontaneous Clarified Individuals, Denotes Previous HCV Infection. PLoS Pathog.13:e1006305. doi: 10.1371/journal.ppat.1006305

37. Scheel, T. K., Luna, J. M., Liniger, M., Nishiiuchi, E., Rozen-Gagnon, K., Shlomai, A., et al. (2016). A Broad RNA virus survey reveals both miRNA dependence and functional sequestration. Cell Host Microbe 19, 409–423. doi:10.1016/j.chom.2016.02.007

38. Tong, L., Lin, L., Wu, S., Guo, Z., Yang, T., Qin, Y., et al. (2013). Mir-10a upregulates coxsackievirus B3 biosynthesis by targeting the 3D-coding sequence. Nucleic Acids Res. 41, 3760–3771. doi:10.1093/nar/gkt058

39. Yang, J. (2019). Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis. Expert. Rev. Clin. Pharmacol. 12, 95–99. doi: 10.1080/17512433.2019.1567326
57. Gallant-Behm CL, Piper J, Dickinson BA, Dalby CM, Pestano LA, Jackson AL. A synthetic microRNA-92a inhibitor (MRG-110) accelerates angiogenesis and wound healing in diabetic and nondiabetic wounds. Wound Repair Regen. 2018;26(4):311-323. doi:10.1111/wrr.12660

58. Li G, Fan Y, Lai Y, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92(4):424-432. doi:10.1002/jmv.25685

59. Sungnak, W., Huang, N., Bécavin, C. et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med 26, 681–687 (2020). https://doi.org/10.1038/s41591-020-0868-6

60. Christopher Muus, et al. (2020). Integrated analyses of single-cell atlases reveal age, gender, and smoking status associations with cell-type-specific expression of mediators of SARS-CoV-2 viral entry and highlights inflammatory programs in putative target cells. Posted on bioRxiv.org on April 20, 2020;10.1101/2020.04.19.049254.

61. Catanzaro, M., Fagiani, F., Racchi, M. et al. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Sig Transduct Target Ther 5, 84 (2020). https://doi.org/10.1038/s41392-020-0191-1

62. Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhhan, China. Lancet. Lond. Engl. 395, 497–506 (2020).

63. Levanova, A., & Poranen, M. M. (2018). RNA Interference as a Prospective Tool for the Control of Human Viral Infections. Frontiers in microbiology, 9, 2151. https://doi.org/10.3389/fmicb.2018.02151

64. Leon-Icaza, Stephen & Zeng, Mingtao & Rosas-Taraco, Adrian. (2019). microRNAs in viral acute respiratory infections: immune regulation, biomarkers, therapy, and vaccines. 1. 7. 10.1184/jn.119.4-0004-7.

65. Mallick B, Ghosh Z, Chakrabarti J. MicroRNAome analysis unravels the molecular basis of SARS infection in bronchoalveolar stem cells. PLoS One. 2009;4:e7837.

66. Martinez M. A. (2020). Compounds with Therapeutic Potential against Novel Respiratory Coronavirus 2019. Antimicrobial agents and chemotherapy, 64(5), e00399-20. https://doi.org/10.1128/AAC.00399-20

67. Agostini, M. L., Andres, E. L., Sims, A. C., Graham, R. L., Sheahan, T. P., De Agostini, M. A. (2020). Compounds with Therapeutic Potential for the Control of Human Viral Infections. 1. 7. 10.1186/s41544-018-0004-7.

68. Wu Y, Wang F, Shen C, et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2 [published online ahead of print, 2020 May 13]. Science. 2020; eabc2241. doi:10.1126/science.abc2241

69. Wang, C., Li W., Drabek, D. et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun 11, 2251 (2020). https://doi.org/10.1038/s41467-020-16256-y

70. Liu, U., Árvalo MT, Diaz-Arvalo D, Chen Y, Choi J-G, Zeng M. Generation of a safe and effective live viral vaccine by virus self-attenuation using species-specific artificial microRNA. J Control Release. 2015; 207:70–6.

71. Liu, C., Zhou, Q., Li, Y., Gao, G. Gene transfer in the lung using recombinant adenovirus-associated virus. Curr Protoc Microbiol. 2012 Aug;Chapter 14:Unit14D.2.

72. Abdel-Ghany, Shaimaa & Sabit, Hussein. (2020). microRNA-Based Vaccination and Treatment for COVID-19. 4. 10.31021/ctcv.20203109.

73. Rational designing asymmetrical siRNAs to target Novel Acute Respiratory Syndrome RNA Coronavirus (COVID-19) for silencing (2020, IP Disclosure) Peixuan Guo (Ohio State University), Guiliang Tang (Michigan Tech University), and Jianjun Zhao (Cleveland Clinic)

74. Methods and compositions for controlling efficacy of RNA silencing. (2019) Phillip D Zamore, Gu, Guiliang Tang Us Patent 10,364,429

75. Zhang L, Hou D, Chen X, et al. Exogenous plant MiR168a specifically targets mammalian LDLR:1 evidence of cross-kingdom regulation by microRNA. Cell Res. 2012; 22: 107–126.

76. Sanchita, Trivedi R, Asif MH, Trivedi PK. Dietary plant miRNAs as an augmented therapy: cross-kingdom gene regulation. RNA Biol. 2018;15(12):1433-1439. doi:10.8002/1097-8747.156307

77. Lingbeck, J. M., O’Bryan, C. A., Martin, E. M., Adams, J. P., & Crandall, P. G. (2015). Sweetgum: An ancient source of beneficial compounds with modern benefits. Pharmacognosy reviews, 9(17), 1–11. https://doi.org/10.4103/0973-7847.156307

78. Cavalleri, D., Rizzetto, L., Tocci, N. et al. Plant microRNAs as novel immunomodulatory agents. Sci Rep 6, 25761 (2016). https://doi.org/10.1038/srep25761

79. Liu T, Zhang L, Joo D, Sun SC. NF-kB signaling in inflammation. Signal Transduct Target Ther. 2017;2:17023-. doi:10.1038/sigtrans.2017.23

80. Si̇mşek Yavuz S, Ünal S. Antiviral treatment of COVID-19. Turk J Med Sci. 2020;50(S1-1):611-619. Published 2020 Apr 21. doi:10.3906/sag-2004-14

81. Wang, X., Cao, R., Zhang, H. et al. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro. Cell Discov 6, 28 (2020). https://doi.org/10.1038/s41421-020-0168-9

82. Hodgson, J. The pandemic pipeline. Nat Biotechnol. 2020;38(5):523-532. doi:10.1038/s41587-020-00854-z

83. Siomi, M. C. (2010). piRNAs (PIWI-interacting RNAs). AccessScience. Retrieved August 22, 2020, from https://accessscience.oup.com/doi/10.1093/2018.1551693

84. Anderson, E. J., Roupheael, N. G., Widge A. T., et al. (2020) Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med. Sep 29

85. Walsh, E. F, French, R. W. Jr, Falsey, A. R., et al. Safety and immunogenicity of two RNA-Based Covid-19 vaccine candidates. N Engl J Med. 2020 Oct 14;NEJMoa2027906. doi: 10.1056/NEJMoa2027906. Epub ahead of print. PMID: 33053279; PMCID: PMC7583697.

86. Kecheh, R., Albert, C., Lapenn, T., et al. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med. 2020 Sep 2;NEJMoa2026920. doi:10.1056/NEJMoa2026920. Epub ahead of print. PMID: 32877575; PMCID: PMC7494251.

87. Mercado, N. B., Zahn, R., Wegmann, F. et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature 586, 583–588 (2020). https://doi.org/10.1038/s41586-020-2607-z

88. Kalinín, K. V., Pšitnik, T., Kishko, M., et al. Immunogenicity of novel mRNA COVID-19 vaccine MRT5500 in mice and 2 non-human primates. BioRxiv 2020.10.14.337535; doi: https://doi.org/10.1101/2020.10.14.337535